Why Acadia Pharmaceuticals Stock Is Soaring Today

Already recovering from weakness suffered aboriginal this year, Acadia Pharmaceuticals (NASDAQ: ACAD) shares were outright catapulted higher today. Indeed, the pharmaceutical stock's 12.2% summation arsenic of 12:17 p.m. ET Friday has pushed it backmost wrong show of its 52-week precocious deed precocious past year.

The punctual for this bullishness? Unsurprisingly, encouraging quality regarding 1 of its 2 approved drugs.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

A caller marketplace is astir to unfastened up

With a marketplace headdress of little than $5 billion, Acadia is thing but a pharmaceutical powerhouse. But, it's not trying to beryllium one. Its absorption is comparatively narrow, aimed astatine underserved uncommon conditions similar neurological upset Rett syndrome, oregon psychosis stemming from Parkinson's illness and Alzheimer's.

To this end, the company's lone 2 treatments presently approved anyplace are Daybue (for Rett) and Nuplazid (for psychosis), which produced gross of $101 cardinal and $167 cardinal -- respectively -- during the archetypal fiscal 4th of this year.

After increasing 20% twelvemonth implicit twelvemonth successful Q1, however, income of Daybue could soon beryllium adjacent higher. On Friday, the institution announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommends its support successful the EU arsenic a attraction for the neurobehavioral symptoms of Rett syndrome. If yet approved, it would beryllium the archetypal attraction permitted successful Europe for this peculiar purpose.

Just beryllium diligent

It's unclear however large Europe's Rett syndrome marketplace is, though fixed what's known astir the U.S. marketplace and Acadia's absorption connected uncommon diseases, it's presumably not enormous.

On the different hand, neither is Acadia Pharmaceuticals, and it faces small to nary existent contention connected either front.

Acadia is besides -- amazingly capable for a pharma institution of its size, age, and ilk -- profitable. It's investigating a fistful of drugs different than Daybue and Nuplazid for the attraction of different uncommon diseases arsenic well, and each of these trials is showing beardown promise. There are surely worse, riskier concern prospects retired there.

The lone arguable downside to stepping into this banal close present is the sheer scope of today's gain, which has near down a sizable spread from Thursday's high. Some investors whitethorn consciousness it needs to beryllium backfilled archetypal earlier shares tin determination higher.